Developing a better understanding of Parkinson’s disease and its various symptoms allows researchers to find new methods enabling earlier diagnosis and better treatment. In order to achieve this important objective, the research team is actively looking for more study participants; both people with Parkinson disease as well as healthy people over the age of 65 years can participate in the study.
Who conducts the study? The Luxembourgish Parkinson Study is a joint Research program of different research institutions in Luxembourg supported by the Fonds National de la Recherche (FNR) with the objective to combine the expert knowledge about the Parkinson disease. Partners are the Centre Hospitalier Luxembourg (CHL), the Integrated Biobank of Luxembourg (IBBL), the Luxembourg Institute of Health (LIH), as well as the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg.
Parkinson patients: tel: 4411-4848; e-Mail: parkinson@chl.lu
Healthy persons (control group): tel: 2697-0889, e-Mail: maura.minelli@lih.lu
keystonemeds(@)protonmail.com ROXICODONE, OPANA, DILAUDID, SUBUTEX, TRAMADOL, FENTANYL, METHADONE, HYDROCODONE, QUAALUDES, SOMA
CAT HOTEL in Munsbach, Schuttrange
Villa in Provence - Côte d'Azur